Wall Street brokerages expect that Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) will announce earnings of ($3.53) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Intercept Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($3.18) and the lowest estimate coming in at ($3.78). Intercept Pharmaceuticals reported earnings per share of ($3.59) during the same quarter last year, which indicates a positive year-over-year growth rate of 1.7%. The company is scheduled to issue its next quarterly earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that Intercept Pharmaceuticals will report full-year earnings of ($14.07) per share for the current fiscal year, with EPS estimates ranging from ($14.80) to ($13.26). For the next financial year, analysts expect that the business will report earnings of ($11.47) per share, with EPS estimates ranging from ($14.81) to ($7.26). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Intercept Pharmaceuticals.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The firm had revenue of $30.89 million during the quarter, compared to analysts’ expectations of $27.50 million. During the same period in the previous year, the firm posted ($3.14) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% on a year-over-year basis.

Several equities research analysts have weighed in on ICPT shares. Credit Suisse Group increased their target price on shares of Intercept Pharmaceuticals from $198.00 to $201.00 and gave the stock an “outperform” rating in a report on Monday, May 15th. Wedbush reiterated an “outperform” rating and issued a $231.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, May 26th. ValuEngine upgraded shares of Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Cowen and Company reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a report on Monday, June 12th. Finally, BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. One analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $205.04.

Intercept Pharmaceuticals (ICPT) traded down 0.11% on Thursday, reaching $117.48. The company had a trading volume of 279,609 shares. The firm has a 50-day moving average of $113.59 and a 200-day moving average of $117.24. Intercept Pharmaceuticals has a 12 month low of $96.63 and a 12 month high of $172.95. The stock’s market capitalization is $2.95 billion.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/07/analysts-expect-intercept-pharmaceuticals-inc-icpt-will-post-earnings-of-3-53-per-share.html.

In related news, CEO Mark Pruzanski sold 40,000 shares of the firm’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $130.80, for a total value of $5,232,000.00. Following the completion of the transaction, the chief executive officer now owns 611,718 shares of the company’s stock, valued at $80,012,714.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Lisa Bright sold 394 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $121.33, for a total transaction of $47,804.02. Following the completion of the transaction, the insider now directly owns 23,619 shares of the company’s stock, valued at approximately $2,865,693.27. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,013 shares of company stock valued at $6,198,747. 9.20% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC grew its position in shares of Intercept Pharmaceuticals by 0.7% in the 2nd quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock valued at $454,094,000 after acquiring an additional 25,958 shares during the period. Carmignac Gestion grew its position in shares of Intercept Pharmaceuticals by 0.4% in the 2nd quarter. Carmignac Gestion now owns 2,035,592 shares of the biopharmaceutical company’s stock valued at $246,449,000 after acquiring an additional 7,400 shares during the period. Vanguard Group Inc. grew its position in shares of Intercept Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after acquiring an additional 57,149 shares during the period. State Street Corp grew its position in shares of Intercept Pharmaceuticals by 7.3% in the 1st quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock valued at $91,110,000 after acquiring an additional 54,523 shares during the period. Finally, First Trust Advisors LP grew its position in shares of Intercept Pharmaceuticals by 17.0% in the 2nd quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock valued at $34,797,000 after acquiring an additional 41,856 shares during the period. 82.19% of the stock is owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get a free copy of the Zacks research report on Intercept Pharmaceuticals (ICPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.